Clinical Trial Search

Primary: Mean Patient-Reported Treatment Satisfaction Questionnaire for Medication Scores (TSQM-9) — 32.0; 44.7 Scores on a scale

Primary: Percentage of Participants With Remission at Week 8 — 18.5; 8.2 percentage of participants — p=0.0070

Primary: Proportion of Patients Dying of Neurological Death, Defined as Dying With Progressive Neurological Dysfunction Regardless of Systemic Disease Status — 5 patients

Primary: Summary of Hemoglobin (Hgb) Concentration at Week 24 — 10.20; 10.64; 10.03; 10.66 grams per deciliter

Primary: Physical Activity Measured by the International Physical Activity Questionnaire (IPAQ) — 407; 1711 MET

Primary: Adverse Events — 6; 2; 1; 0 participants

Primary: Overall Response Rate Defined as Complete or Partial Response as Assessed by RECIST Version 1.0 Criteria. — 38.1; 0 percentage of patients

Primary: Composite Success of Improvement in New York Heart Association (NYHA) Class and a Performance Goal for Effective Orifice Area (EOA). — 93.6; 91.7 percentage of…

Primary: Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) Total Score — 26.00; 24.47; 14.25; 15.16 units on a scale

Primary: Maximum Tolerated Dose (MTD) of Lenalidomide — 100 mg/day

Primary: Change From Baseline in Glucagon-stimulated C-peptide AUC at 24 Months — -3.848; -4.348 nmol*minute/L — p=0.2851

Primary: Cobalt Chromium Levels — 1.06 micrograms/dl

Primary: Post-operative Pain on the Visual Anlogue Scale (VAS) at the 6-hour Post-operative Interval — 5; 3.2; 3.5 units on a scale

Primary: Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) National Glycohemoglobin Standardization Program (NGSP) at the End of Treatment (EOT) Period — 0.16; -0.49…

Primary: Virologic Response (VR) — 14.3; 22.2; 55.6; 88.9 percentage of participants